References
1. Cronin, K.A., et al., Annual
report to the nation on the status of cancer, part 1: National cancer
statistics. Cancer, 2022. 128 (24): p. 4251-4284.
2. Janardan, S.K. and T.P. Miller,Adolescents and young adults (AYAs) vs pediatric patients:
survival, risks, and barriers to enrollment. Hematology Am Soc Hematol
Educ Program, 2023. 2023 (1): p. 581-586.
3. Ferrari, A., et al.,Adolescents and young adults with rhabdomyosarcoma treated in the
European paediatric Soft tissue sarcoma Study Group (EpSSG) protocols: a
cohort study. Lancet Child Adolesc Health, 2022. 6 (8): p.
545-554.
4. Harrison, D., et al.,Adolescents and Young Adults with Rhabdomyosarcoma: A Report from
the Soft Tissue Sarcoma Committee of the Children’s Oncology Group Short
Running Title: Rhabdomyosarcoma in the AYA Population. Pediatr Blood
Cancer, 2024. in press .
5. Trama, A., et al., Survival
of European adolescents and young adults diagnosed with cancer in
2000-07: population-based data from EUROCARE-5. Lancet Oncol, 2016.17 (7): p. 896-906.
6. Kirchhoff, A.C., et al.,Access to Care for Adolescent and Young Adults With Cancer in the
United States: State of the Literature. J Clin Oncol, 2023: p.
JCO2301027.
7. Ferrari, A., et al., Shedding
a Light on the Challenges of Adolescents and Young Adults with
Rhabdomyosarcoma. Cancers (Basel), 2022. 14 (24).
8. Valtis, Y.K., et al.,Treatment completion, asparaginase completion, and oncologic
outcomes among children, adolescents and young adults with acute
lymphoblastic leukemia treated with DFCI Consortium Protocols.Leukemia, 2024.
9. Sultan, I., et al., Comparing
adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology
and end results program, 1973 to 2005: an analysis of 2,600 patients. J
Clin Oncol, 2009. 27 (20): p. 3391-7.
10. Shern, J.F., et al.,Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A
Report From an International Consortium. J Clin Oncol, 2021.39 (26): p. 2859-2871.